1H-Indene-2-carboxylic acid, 4-[[(2R,6S)-2,6-dimethyl-4-[4-(trifluoromethoxy)phenyl]-1-piperazinyl]sulfonyl]-2,3-dihydro-, rel-, 4-methylbenzenesulfonate (1:1)

KD-3010 is a peroxisome proliferator-activated receptor delta agonist potentially for the treatment of diabetes and obesity. KD-3010 dramatically ameliorates liver injury induced by carbon tetrachloride (CCl(4)) injections. Deposition of extracellular matrix proteins was lower in the KD3010-treated group than in the vehicle- or GW501516-treated group. Interestingly, profibrogenic connective tissue growth factor was induced significantly by GW501516, but not by KD-3010, following CCl(4) treatment.